{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "KMTS",
  "name": "Kestra Medical Technologies, Ltd.",
  "url": "https://orbyd.app/dossiers/KMTS/",
  "json_url": "https://orbyd.app/dossiers/KMTS.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "Wearable-defibrillator share-capture story accelerating: FY26 revenue $95.1M (+59%), fiscal Q4 $28.6M (+66%) with gross margin 54.8% vs 44.3%, plus JPMorgan's 2026-08-10 Overweight/$30 initiation. Price closed $26.99 on 2026-08-21, 4.8% off the 52-week high. The ~2026-09-10 Q1 FY27 print is the first test of the $137M FY27 guide (+44%, a deceleration).",
  "invalidation_trigger": "A weekly close below $24 marks the post-guidance advance as failed (roughly 15% under the $28.35 52-week high). Secondary: the Q1 FY27 print around 2026-09-10 comes and goes with the $137M FY27 guide unchanged and prescription growth decelerating toward +44% YoY.",
  "catalyst_date": "2026-09-10",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Fiscal year ends April 30. 'FY27' covers May 2026-April 2027; quarterly results have landed in September, December, March and July.",
    "58,602,497 common shares outstanding as of 2026-07-09 per the FY26 annual report cover page.",
    "Essentially all revenue derives from the ASSURE WCD system and its associated monitoring service - single-product concentration.",
    "Several executives sell under pre-adopted 10b5-1 plans; July-August 2026 Form 4/144 flow is scheduled rather than discretionary.",
    "Bain Capital is the largest holder at roughly 46% of shares outstanding per August 2026 ownership tallies."
  ],
  "body_markdown": "## Current Thesis\nThe leg on offer is share capture in wearable cardioverter defibrillators (WCD) with gross margin inflecting at the same time. Kestra's ASSURE system generated FY26 revenue of $95.1M, +59% versus FY25, with fiscal Q4 (quarter ended 2026-04-30) revenue of $28.6M, +66% YoY, and Q4 gross margin of 54.8% against 44.3% a year earlier — all reported 2026-07-14. Management guided FY27 revenue to $137M, +44%. JPMorgan started coverage Overweight with a $30 target on 2026-08-10, the first bulge-bracket sponsorship on the name. Price closed 2026-08-21 at $26.99, 4.8% under the $28.35 52-week high, up 24.7% over three months, RSI(14) at 67.8. The first test of the FY27 guide is the Q1 print, expected in the second week of September (prior-year Q1 landed 2025-09-11).\n\nLife-cycle read: **ACCELERATING**. What dates it — the 2026-07-14 FY26 release (first full year of guided numbers as a public company), the 2026-08-10 JPMorgan initiation adding new institutional coverage, and price holding within 5% of its 52-week high three weeks later. Attention is being added, not recycled.\n\n## Bull Case\n- Fiscal Q4 FY26 revenue $28.6M, +66% YoY; FY26 $95.1M, +59% versus FY25 (2026-07-14 release).\n- Gross margin moved from 44.3% to 54.8% in the fiscal Q4 comparison, and from 40.5% to 51.4% at the full-year level — the operating leverage is showing up in the reported line, not only in commentary.\n- Unit demand tracks the revenue: ASSURE prescriptions of 6,357 in fiscal Q4, +63% YoY, and 20,720 for FY26, +57%. Company attributed growth to \"higher market share and WCD market expansion.\"\n- FY27 guidance of $137M was set above the sell-side FY27 figure of roughly $135.55M cited in post-print coverage — a guide above the number, unusual for a first-year public medtech.\n\n- JPMorgan's 2026-08-10 Overweight and $30 target sits roughly 11% above the 2026-08-21 close of $26.99.\n\n## Bear Case\n- The guide itself is the deceleration: +44% for FY27 against +59% for FY26 and +66% in fiscal Q4. Multiple compression on decelerating growth is the standard path for names like this, and the September print is the first place it can show.\n- Losses widened in dollars while margins improved: FY26 GAAP net loss $131.6M versus $113.8M in FY25; adjusted EBITDA loss $87.0M versus $68.4M.\n- Debt arrived before profitability.\n- Insider supply into strength is observable and dated: CEO Brian Webster sold 15,000 shares on 2026-08-17 at an average of $27.48 under a 10b5-1 plan adopted 2025-09-29, leaving 460,215 shares. Separate Rule 144 notices from other insiders cluster across July and August 2026, several tied to July 2026 PSU vesting.\n- Sponsor concentration: Bain Capital is the largest shareholder at roughly 46% of shares outstanding per August 2026 ownership tallies — a persistent overhang of registrable stock.\n- Sell-side is not uniformly constructive. A 2026-08-20 rating aggregation put the consensus at \"Hold,\" so the JPMorgan Overweight is the outlier rather than the group view. Simply Wall St published a July 2026 piece arguing the shares could be ~31% overvalued once the FY27 guide was in the model — an attributed third-party valuation view, not a measurement.\n- Single-product concentration on ASSURE against an entrenched incumbent (ZOLL's LifeVest) means one reimbursement or competitive change reprices the whole story.\n\n## Setup & Price Structure\n- Reference close 2026-08-21: $26.99. 52-week high $28.35, so price is 4.8% below it. Three-month price change of +24.7%. RSI(14) 67.8 — the upper band, short of the >75 zone where reversals cluster.\n- The structure is a post-print advance that has held: FY26 numbers landed 2026-07-14, coverage was added 2026-08-10, and price has not given the move back. The unresolved level is $28.35 — a weekly close through it puts the JPMorgan $30 target in play as the next reference.\n- Crowding observables, stated as observables: RSI(14) at 67.8 with price inside 5% of the 52-week high; an earnings print expected within roughly three weeks; scheduled insider distribution running through July–August 2026 including a CEO sale at $27.48 on 2026-08-17; a single Overweight against a \"Hold\" consensus tally dated 2026-08-20. That combination describes a name where new buyers are arriving into supply that is already programmed.\n- Downside reference: $24 is roughly 11% under the last close and roughly 15% under the 52-week high. A weekly close under it would mean the entire bid that arrived with the 2026-08-10 initiation has been absorbed.\n\n## Catalyst Calendar (next 30 days)\n- **~2026-09-10 (est.)** — Q1 FY27 results and conference call, quarter ended 2026-07-31. No date confirmed by the company as of 2026-08-22; the estimate follows the prior-year cadence (Q1 FY26 was released 2025-09-11, Q2 FY26 on 2025-12-11). This print carries the first prescription and revenue datapoint against the $137M FY27 guide; sell-side had roughly $28.59M pencilled for the quarter.\n- **Through 2026-09-30** — continued Form 4 and Rule 144 filings from executives selling under existing 10b5-1 plans. Not a thesis event on its own; relevant as the supply side of the current advance.\n\n## What Would Change Our Mind\nThe structural break is the September quarter landing at or below the sell-side ~$28.59M with prescription growth decelerating toward the guided +44% full-year pace rather than holding the +63% YoY it printed in fiscal Q4. A reiterated-but-not-raised $137M FY27 guide alongside a widening adjusted EBITDA loss would say the margin inflection is being spent rather than banked. On price, a weekly close below $24 marks the post-guidance advance as failed and removes the technical case entirely; that level sits well under both the $28.35 high and the $26.99 close of 2026-08-21. A second condition, independent of price: the catalyst comes and goes on or around 2026-09-10 without the FY27 guide moving up, while the \"Hold\" consensus tally dated 2026-08-20 stays intact — at that point the narrative has been priced without new fuel, and the label moves toward MATURING. Conversely, a raised FY27 guide plus a second bulge-bracket initiation would extend the accelerating phase.\n\n## Correlation Notes\n- Behaves as a small-cap unprofitable medtech growth name — closest read-across is to cardiac monitoring and rhythm-device peers (iRhythm and similar single-category device franchises), which trade on prescription/procedure volume prints rather than on macro data.\n\n- No meaningful linkage to the AI or semiconductor complexes; the name will not track that beta either way.\n- Reimbursement headlines affecting the WCD category (CMS coverage or fee-schedule changes) would hit KMTS and the incumbent WCD franchise together, independent of relative execution.",
  "first_seen": "2026-08-21",
  "last_analyzed": "2026-08-22T07:16:47+00:00",
  "last_synthesized": "2026-08-22",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}